$VKTX
it's reported that by 2030, the total market for NASH is 160B and total market for obesity is 100B. So this company has basically cover two of the highest potential blockbuster markets with a 260B$ combined addressable market. Imagine the potential of getting a piece of that pie.
San Diego-based Viking (VKTX) is developing a GLP-1 receptor agonist in both injectable and oral form as a treatment for obesity and diabetes. The new class of drugs have proved highly popular and boosted the stocks of the two companies leading the sector, Eli Lilly & Co. (LLY) and Denmark's Novo Nordisk (NVO) (DK:NOVO.B).
No comments:
Post a Comment